Anti-Covid oral drug by DRDO gets DGCI approval

As India fights the second wave of the pandemic, which is killing thousands every day, the country’s top drugs controller has approved a drug developed by the DRDO (Defense Research and Development Organisation) for emergency use.

INMAS, a Defence Research and Development Organization (DRDO), developed this drug in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad. The drug has already undergone clinical trials, and the molecule has been shown to aid in the faster recovery of hospitalised patients.

The drug comes in powdered form and is mixed with water and swallowed.

The anti-Covid therapeutic application of the drug 2-deoxy-D-glucose was developed by a DRDO lab and Hyderabad-based Dr Reddy’s Laboratories (2-DG).

After clinical trial findings showed that a molecule present in the drug aids in the faster recovery of hospitalised patients and decreases supplementary oxygen dependency, the Drugs Controller General of India (DCGI) approved the drug.

Between May and October of this year, the drug was discovered to be effective in this study group of nineteen COVID patients and significantly enhanced their recovery. The second phase of the experiment was done in 110 patients. While the third phase of trials was being conducted in six locations, a “dose intensification” trial was also being carried out in 11 locations across India.

The sudden rise in COVID infections has left India with a global shortage of life-saving drugs, oxygen, and other medical necessities, and India has sent massive amounts of humanitarian aid in response.

Leave a Reply